Ever since the first time they were used in Osaka in 1976 until present day, statins have shown to be an effective, useful and safe class of medicine. Their significance to public health is best manifested by a constant rise in prevalence of dyslipidemias in the modern society, as well as cardiovascular diseases having the highest mortality in the general population. By inhibition of cholesterol and isoprenoid precursor synthesis, statins cause significantly faster reduction in the risk of coronary incident repetition through a number of so called pleiotropic effects. Even though their physical attributes differ, statins share a common pharmacodynamic mechanism of action, which means that in personalizing the therapy other factors are taken into consideration, such as serum lipid levels (LDL, HDL), liver and kidney condition and present therapy so that potential interactions can be avoided. The aim of this thesis was to assay the antioxidative effect of atorvastatin, fluvastatin, pravastatin and simvastatin by measuring their capacity to scavenge 1,1-diphenyl-2-picrylhydrazyl radical, in the function of testing the potential additional positive effects. The method of use is based on measuring the decrease in apsorbance of DPPH which occurs during the transfer of electrons from the radical to a potential antioxidant (the investigated statin molecules). All samples were prepared as 1 mM solutions, analysed in triplicates, and results expressed in the form of antioxidative capacity equivalent to TROLOX standards. Based on the results, atorvastatin, fluvastatin, pravastatin and simvastatin have demonstrated a measurable in vitro antioxidative activity. Method of analysis using HPLC-DAD system has presented itself to be quick, reliable and effective in assaying the antioxidative activity of medicines from the statin group.